Stryker shares tumble despite strong Q2 results and raised guidance
On Thursday, Canaccord Genuity adjusted its price target on Teladoc Health Inc. (NYSE:TDOC) shares, reducing it to $12 from the previous $14, while maintaining a Buy rating on the stock. Currently trading at $7.19, the stock has seen a challenging year with a 43.87% decline over the past 12 months. According to InvestingPro analysis, Teladoc appears undervalued based on its Fair Value metrics. The adjustment follows Teladoc’s recent quarterly financial results, which surpassed both Canaccord’s projections and the consensus estimates, especially in the Integrated Care segment.
Teladoc’s acquisition of UpLift, a virtual mental health provider, was a highlight of the quarter. This move is expected to provide in-network coverage for Teladoc’s BetterHelp business, making it a more affordable option for users who previously bypassed the subscription due to cost concerns. With a robust gross profit margin of 70.76% and moderate debt levels, Teladoc appears well-positioned to integrate this acquisition. Canaccord believes that this acquisition will lead to greater customer conversion and retention, which will ultimately contribute to increased gross margin dollars.
The company reported a total membership of 102.5 million, exceeding estimates and expanding its potential for cross-selling. However, Teladoc also experienced a setback with a sequential decrease of about 52,000 in Chronic Care program enrollment, which raises concerns, particularly in light of a contract loss disclosed in the previous quarter that will impact results starting in the second quarter of 2025.
Despite these challenges, Canaccord remains optimistic about Teladoc’s prospects, citing the company’s large base of U.S. Integrated Care members as a significant competitive advantage. The analyst firm views 2025 as a turnaround year for Teladoc and believes that the current valuation presents a favorable risk/reward scenario for investors. InvestingPro data reveals the company maintains a healthy current ratio of 1.77 and has received a "GOOD" overall financial health score, suggesting operational stability despite current market challenges. For deeper insights into Teladoc’s financial health and growth potential, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro.
Management at Teladoc anticipates a $10-15 million impact on 2025 adjusted EBITDA due to the investments required for the UpLift acquisition. Nevertheless, Canaccord is confident in the company’s ability to leverage its comprehensive offerings, including next-generation cardiometabolic solutions and weight management programs, to strengthen its market position.
In other recent news, Teladoc Health Inc. reported a first-quarter 2025 net loss per share of $0.53, which was below analysts’ expectations of a $0.34 loss. Despite this, the company’s revenue of $629.4 million slightly surpassed forecasts of $619.33 million, indicating a stronger-than-expected sales performance. Teladoc has also made a strategic move by acquiring Uplift, a virtual mental health company, for $30 million. This acquisition is anticipated to enhance Teladoc’s Behavioral Health capabilities in the insured market, aligning with its priority of expanding virtual mental health services.
Citi analyst Daniel Grosslight recently adjusted Teladoc’s price target to $8.00 from $8.75 but maintained a Buy rating on the stock, citing a strong quarter with significant membership growth. The acquisition of Uplift is viewed as a significant step towards expanding Teladoc’s reach in the behavioral health segment. Teladoc continues to hold a strong cash position with nearly $1.2 billion in cash and equivalents, providing financial flexibility for future strategic initiatives. The company reaffirmed its full-year 2025 revenue guidance of $2.47 to $2.58 billion and adjusted EBITDA guidance of $263 to $304 million. Despite the challenges, Teladoc remains focused on expanding insurance coverage and penetrating international markets.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.